New York, Sept. 16, 2015 (GLOBE NEWSWIRE) -- Allovate, LLC, a specialty biopharmaceutical company focused on improving treatment for allergies, announced today that results of a clinical trial of oral mucosal immunotherapy (OMIT), delivered via its lead product, Allerdent®, will be presented on Friday, September 25, 2015 at the American Academy of Otolaryngic Allergy (AAOA) Annual Scientific Meeting in Dallas, TX.
Dr. William Reisacher, Associate Professor of Otolaryngology at Weill Cornell Medical College and Chief Scientific Advisor to Allovate, will present the data as part of the Scientific Program of the AAOA's Annual Scientific Meeting.
Title: Oral Mucosal Immunotherapy (OMIT) For Allergic Rhinitis: Safety, Efficacy And Adherence
Presenter: William Reisacher, MD
Date: Friday, September 25, 2015
Time: 3:00 pm
About Allergy Immunotherapy
Respiratory allergies affect at least 60 million people in the United States, resulting in 11.1 million visits to the doctor in 2010. Symptomatic treatment, at a global cost of over $25 billion yearly, keeps symptoms at bay temporarily but does not offer a long-term solution. Allergen-specific immunotherapy is the only treatment method that targets the root cause of the disease, consistently exposing the allergy sufferer's immune system to small amounts of allergen proteins to desensitize them to the allergens over time. Immunotherapy has traditionally been administered by injecting allergens into the skin (subcutaneous immunotherapy (SCIT)) or placing them under the tongue (sublingual immunotherapy (SLIT)). Oral mucosal immunotherapy (OMIT) requires a specially formulated toothpaste to stabilize allergenic extracts and offers advantages over existing approaches to allergy immunotherapy. OMIT simplifies the necessary long-term daily adherence to immunotherapy. It also delivers extracts to the areas of the oral cavity with the highest density of the specialized immune cells that are responsible for initiating desensitization.
About Allovate, LLC
Allovate, LLC is a New York City-based specialty biopharmaceutical company founded in 2012 to improve allergy treatment for all patients. Allovate's aim is to provide safe, effective, and convenient new options for allergy sufferers that deliver demonstrable improvements to therapeutic adherence and clinical outcomes over existing allergy treatment protocols. Allovate's lead product, Allerdent®, is designed to deliver proteins, such as immunotherapeutic agents, to the immune system while the user brushes their teeth.
Dr. Reisacher has an equity ownership in Allovate and serves as an unpaid consultant to the company.